Previous 10 | Next 10 |
HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7 th at 9:00 am ET. A webcast of the presentation will be available on the " ...
HAMPTON, N.J., May 31, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-585. CDX-585 combines highly active PD-1 blockade with anti-ILT4 blockade to overcome immunosuppressive signals in T cells and m...
2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...
2023-05-18 11:27:48 ET Summary Celldex Therapeutics is at the forefront of the immuno-oncology revolution, leveraging its innovative pipeline to develop groundbreaking immunotherapies for the treatment of cancer. The company's flagship product, CDX-585, combining PD-1 and ILT4 blo...
HAMPTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced preclinical data from CDX-622, the Company’s bispecific antibody with dual targeting of the alarmin TSLP and stem cell factor (SCF), also known as KIT receptor ligand, developed from it...
2023-05-04 17:14:58 ET Celldex press release ( NASDAQ: CLDX ): Q1 GAAP EPS of -$0.62. Revenue of $1M (-94.2% Y/Y). Cash, cash equivalents and marketable securities as of March 31, 2023 were $278.4 compared to $305.0 million as of December 31, 2022. Financial Guidan...
- Phase 2 CSU enrollment completion expected in Q3 2023 - - Phase 1b CSU study and Phase 1 cholinergic cohort both accepted for oral presentation at EAACI 2023 - - Phase 2 EoE study expected to initiate in June 2023 - HAMPTON, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Celldex Thera...
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30 th at 11:30 am ET. A webcast of ...
The following slide deck was published by Celldex Therapeutics, Inc. in conjunction with this event. For further details see: Celldex Therapeutics (CLDX) Presents At AAAAI Conference
Celldex press release ( NASDAQ: CLDX ): Q4 GAAP EPS of -$0.56 beats by $0.03 . Revenue of $1.61M (+387.9% Y/Y) beats by $1.35M . Cash, cash equivalents and marketable securities as of December 31, 2022 were $305.0 million compared to $323.5 million as of September 30, ...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...